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Following a fibrogenic stimulus, the hepatic stellate
cell (HSC) undergoes a complex activation process asso-
ciated with increased cell proliferation and excess dep-
osition of type I collagen. The focal adhesion kinase
(FAK)-phosphatidylinositol 3-kinase (PI3K)-Akt signal-
ing pathway is activated by platelet-derived growth fac-
tor (PDGF) in several cell types. We investigated the role
of the FAK-PI3K-Akt pathway in HSC activation. Inhibi-
tion of FAK activity blocked HSC migration, cell attach-
ment, and PDGF-induced PI3K and Akt activation. Both
serum- and PDGF-induced Akt phosphorylation was in-
hibited by LY294002, an inhibitor of PI3K. A constitu-
tively active form of Akt stimulated HSC proliferation in
serum-starved HSCs, whereas LY294002 and dominant-
negative forms of Akt and FAK inhibited PDGF-induced
proliferation. Transforming growth factor-, an inhibi-
tor of HSC proliferation, did not block PDGF-induced
Akt phosphorylation, suggesting that transforming
growth factor- mediates its antiproliferative effect
downstream of Akt. Expression of type I collagen pro-
tein and 1(I) collagen mRNA was increased by Akt ac-
tivation and inhibited when PI3K activity was blocked.
Therefore, FAK is important for HSC migration, cell
attachment, and PDGF-induced cell proliferation. PI3K
is positioned downstream of FAK. Signals for HSC pro-
liferation are transduced through FAK, PI3K, and Akt.
Finally, expression of type I collagen is regulated by the
PI3K-Akt signaling pathway.
Liver fibrosis represents a wound-healing process in re-
sponse to a variety of chronic stimuli. Fibrosis is characterized
by an excessive deposition of extracellular matrix proteins, of
which type I collagen predominates. Activation of the hepatic
stellate cell (HSC),1 a perisinusoidal cell that resides in the
liver in a quiescent state, is responsible for the increased syn-
thesis and deposition of type I collagen in the liver. Following a
fibrogenic stimulus, the HSC undergoes a complex activation
process in which the cell changes from a quiescent vitamin
A-storing cell to an activated myofibroblast-like cell, which
proliferates and becomes fibrogenic (1, 2). An increase in DNA
synthesis and cell proliferation occurs with HSC activation.
Altered collagen synthesis, at both the mRNA and protein
levels, is observed with a dramatic increase in type I collagen
and smaller but significant increases in type III and IV
collagens (3–5).
Platelet-derived growth factor (PDGF) is the most potent
proliferative cytokine for the HSC (1). Liver fibrosis is associ-
ated with an increase in PDGF protein expression and in-
creased PDGF receptor expression (6). PDGF receptors contain
intrinsic tyrosine kinase activity and, upon binding to its li-
gand, become autophosphorylated at tyrosine residues (7).
PDGF has been shown to transmit proliferative signals in
several cell types, including the HSC (8, 9). The activated
PDGF receptor acts as a high affinity binding site for several
signaling molecules leading to activation of Ras, followed by
activation of Raf, MEK, and ERK (10).
Focal adhesion kinase (FAK) has a key role in the synergistic
interaction between growth factor and integrin signaling path-
ways. FAK, a 125-kDa cytoplasmic protein-tyrosine kinase, is a
member of the focal adhesion family that mediates integrin-
mediated signal transduction leading to a variety of cellular
functions, including cell proliferation, migration, and adhesion
(11). PDGF induces tyrosine phosphorylation of FAK (12). As-
sociation of FAK and phosphatidylinositol 3-kinase (PI3K) is
stimulated by PDGF and is required for PDGF stimulation of
HSC proliferation (13, 14). Focal adhesion non-kinase (FAK-
CD) represents a kinase-deficient splice variant of FAK that
contains only the C-terminal portion of FAK and that can
inhibit phosphorylation of endogenous FAK, therefore acting as
a dominant-negative form of FAK (11, 15).
PI3K represents another key signaling molecule that is re-
cruited to the activated PDGF receptor (16). Activated PI3K
generates several phosphoinositols, leading to Akt activation
by phosphorylation at Thr308 and Ser473 by phosphoinositide-
dependent kinase-1 (17). Activated Akt is considered a key
downstream survival factor by stimulating cell proliferation
and inhibiting apoptosis (17). Akt is activated not only by
growth factors that stimulate tyrosine kinase activity, but also
by other signals that can activate PI3K, such as integrins and
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stimulators of G-protein-coupled receptors (18–21).
We report here that FAK, PI3K, and Akt are involved in
transmitting proliferative signals induced by serum and PDGF
in the HSC. We show that both serum and PDGF induce
phosphorylation of FAK, PI3K, and Akt and that PI3K and Akt
signal downstream of FAK in the HSC. Blocking either FAK or
PI3K inhibits HSC adhesion and migration. We demonstrate
that PI3K activation is important for both type I collagen
mRNA and protein expression in the HSC. Inhibition of PI3K
reduces secreted type I collagen protein expression, whereas
the intracellular unprocessed collagen intermediates remain
unchanged. Therefore, this signaling pathway is critical for
HSC proliferation and type I collagen gene expression in the
activated HSC.
EXPERIMENTAL PROCEDURES
HSC Isolation and Culture—HSCs were purified from Sprague-Daw-
ley rats (400 g) by sequential digestion of the liver with Pronase and
collagenase, followed by arabinogalactan gradient centrifugation as
previously described (22). HSC purity was assessed microscopically and
by using the autofluorescence property of the stored retinoids in the
HSC. Cell viability was determined by trypan blue exclusion staining.
HSC populations were consistently found to be between 90 and 99%
pure and 95% viable. HSCs were cultured on plastic in Dulbecco’s
modified Eagle’s medium (Invitrogen) supplemented with 10% fetal
bovine serum (FBS) and 2 mM L-glutamine in a 95% air and 5% CO2
humidified atmosphere. HSCs were activated by culturing on plastic for
7–14 days. The purity of culture-activated HSCs was assessed by im-
munohistochemistry using mouse anti-human smooth muscle -actin
(Dako Corp., Carpinteria, CA).
Adenoviral Transduction of HSCs—Ad5LacZ, which contains the
-galactosidase gene driven by the cytomegalovirus promoter, was used
as a control virus throughout this study. The Ad5FAK-CD virus con-
tains the dominant-negative form of FAK (23). The Ad5myrAkt and
Ad5dnAkt viruses express activated and dominant-negative forms of
Akt, respectively (24, 25). Quiescent HSCs, 1 day after isolation (day 1),
were infected with Ad5FAK-CD or Ad5LacZ at a multiplicity of infec-
tion (m.o.i.) of 500 for 12 h in Dulbecco’s modified Eagle’s medium
containing 10% FBS. After infection, the medium was changed to fresh
growth medium. For proliferation and apoptosis studies, culture-acti-
vated HSCs (day 15) were infected at m.o.i.  500 in medium containing
0.2% FBS. After 12 h, the medium was changed to fresh medium
containing 0.2% FBS, and the cells were incubated for an additional
24 h prior to performing the individual experiments.
Immunostaining—HSCs were seeded onto glass coverslips and in-
fected with AdFAK-CD at m.o.i.  500. After 24 h of infection, the
coverslips were washed twice with cold phosphate-buffered saline
(PBS), and the cells were fixed and permeabilized with cold methanol
for 8 min. The methanol was removed, and the coverslips were air-dried
at room temperature. Immunostaining was performed using the Dako
Envision system peroxidase staining kit as directed by the manufac-
turer. Coverslips were washed once with PBS containing 0.2% Tween
20 and then incubated with peroxidase-blocking reagent at room tem-
perature for 5 min. Coverslips were gently washed with PBS containing
0.2% Tween 20 and subsequently incubated with anti-hemagglutinin
antibody (Roche Molecular Biochemicals) at a 1:200 dilution in PBS and
1% bovine serum albumin (BSA) at room temperature for 10 min.
Coverslips were washed and incubated with the peroxidase-labeled
polymer at room temperature for 10 min and washed as described
above. The substrate/chromogen solution was prepared according to the
manufacture’s protocol and incubated on the coverslips at room tem-
perature for 10 min, and the slides were washed with water. The
3,3-diamino benzidine/enhancer solution was added, incubated at room
temperature for 5 min, and then washed with water. The coverslips
were counterstained with hematoxylin for 30 s, rinsed well with water,
and dried for 10 min. The slides were dehydrated with two 100%
ethanol washes for 20 s each and finally with xylene for 20 s. The
coverslips were mounted onto glass slides and viewed microscopically.
Analysis of DNA Synthesis—DNA synthesis was assessed by [3H]thy-
midine incorporation. This assay was used to assess cell proliferation,
as cell counts correlated with the results of the [3H]thymidine incorpo-
ration assay (data not shown). Culture-activated HSCs (7–10 days in
culture) were seeded at a density of 2  104 cells/well in 24-well plates
in growth medium containing 10% FBS. After 24 h, the medium was
changed to 0.2% FBS, and the cells were infected with either
Ad5FAK-CD or Ad5LacZ at m.o.i.  500. The medium was changed
after 12 h to medium containing 0.2% FBS, and the cells were incubated
for an additional 24 h. Afterward, the cells were incubated in medium
containing 10 ng/ml human PDGF-BB (Roche Molecular Biochemicals)
for 48 h with 1 Ci/ml [3H]thymidine present during the last 24 h. At
the end of the incubation, 10% trichloroacetic acid was added, and the
cells were maintained on ice for 15 min. Cells were washed twice with
cold 10% trichloroacetic acid and solubilized in 0.2 N NaOH, and radio-
activity was measured using a scintillation counter. Each experiment
was performed in quadruplicate and repeated at least three times.
Cell Migration Assay—Cell migration was assessed by measuring the
repair of a linear wound generated in a confluent monolayer of HSCs
(26). Parallel lines were drawn on the bottom of wells before plating the
cells. A linear wound was generated in the monolayer of cells by scrap-
ing a sterile plastic pipette tip perpendicular to the lines. The distance
between the wound and cell front was measured with a micrometer,
using the lines on the bottom of the well as a reference, immediately
after creating the wound and 24 h later. Activated HSCs were unin-
fected, infected with the Ad5LacZ or Ad5FAK-CD virus for 24 h before
generating the wound, or treated with the PI3K inhibitor 25 M
LY294002 (Calbiochem) or vehicle (Me2SO) 30 min before generating
the wound. To assure that wound closure represents migration and not
cell proliferation, HSCs were treated with 2.5 g/ml mitomycin C 2 h
before creating the wound.
Cell Adhesion Assay—Culture-activated HSCs were uninfected, in-
fected with the Ad5LacZ or AdFAK-CD virus, or treated with 25 M
LY294002 or Me2SO. Twenty-four hours after infection or 30 min after
LY294002 or Me2SO treatment, HSCs were detached from the culture
dishes with trypsin, and the detached cells were suspended in Dulbec-
co’s modified Eagle’s medium containing 10% FBS. The cells were
replated on tissue culture dishes. Two hours after replating, the cells
were washed twice with PBS to remove unattached cells, and the
adherent cells were trypsinized and counted.
FAK Immunoprecipitation and Western Blotting—HSCs were lysed
with radioimmune precipitation assay buffer (50 mM Tris-HCl (pH 8.0),
150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS,
1 mM Na3VO4, 10 g/ml aprotinin, and 10 g/ml leupeptin). The lysate
was centrifuged at 4 °C for 10 min, and protein concentration was
determined using the Bradford method (Bio-Rad). Cell lysate (250 g)
was incubated with 30 l of anti-FAK antibody (specific for the N
terminus of FAK) and with protein A/G-Sepharose beads (Santa Cruz
Biotechnology, Santa Cruz, CA) at 4 °C for 3 h. The beads were washed
three times with radioimmune precipitation assay buffer, boiled for 5
min in SDS buffer, and applied to standard 10% SDS-polyacrylamide
protein gel. After electrophoresis, the proteins were electrophoretically
transferred onto nitrocellulose membranes (Schleicher & Schüll) using
a Transblot apparatus in buffer containing 20 mM glycine and 20%
methanol. The membrane was stained with 0.5% Ponceau S to assure
equal loading of the gel and transfer of the proteins. The membrane was
blocked with 3% BSA in Tris-buffered saline (TBS; 25 mM Tris-HCl (pH
8.0) and 144 mM NaCl) containing 0.1% Tween 20 (TBS-T) at room
temperature for 45 min. Afterward, the membrane was incubated with
the primary antibody: anti-FAK polyclonal antibody (Santa Cruz Bio-
technology) diluted 1:1000 in 1% BSA in TBS-T or anti-phosphotyrosine
monoclonal antibody (Transduction Laboratories, Lexington, KY) di-
luted 1:2000 in 1% BSA in TBS-T at room temperature for 45 min. The
membrane was washed five times with TBS-T and incubated with
horseradish peroxidase-conjugated anti-goat or goat anti-mouse anti-
body (Amersham Biosciences) diluted 1:5000 in 1% BSA in TBS-T at
room temperature for 30 min. The membrane was washed five times
with TBS-T, and signals were detected using the ECL Western blot
detection system kit (Amersham Biosciences) according to the manu-
facturer’s recommended protocol.
PI3K Assay—Culture-activated HSCs were lysed in buffer contain-
ing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 2 mM EDTA, 1% sodium
deoxycholate, 1% Triton X-100, and 0.25% SDS. The cell lysate (500 g)
was incubated overnight at 4 °C with anti-PI3K p110 antibody (Santa
Cruz Biotechnology). Antigen-antibody immune complexes were cap-
tured with protein A/G-Sepharose beads at 4 °C for 2 h. The beads were
washed three times with 1% Nonidet P-40 and 100 M Na3VO4 in PBS;
twice with 100 mM Tris-HCl (pH 7.5), 500 mM LiCl, and 100 M Na3VO4;
and twice with 100 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM EDTA,
and 100 mol/liter Na3VO4. The beads were centrifuged at 16,000  g
for 1 min at room temperature and suspended in 50 l of 10 mM
Tris-HCl (pH 7.5), 100 mM NaCl, and 1 mM EDTA and 10 l of 10 mM
MgCl2 to which 10 l of a 2 M solution of phosphatidylinositol (Avanti,
Pelham, AL) was added. The reaction was initiated by adding 5 l of
440 M ATP and 15 l of [32P]ATP (3000 Ci/ml), and the reaction
FAK-PI3K-Akt and HSC Proliferation and Collagen Expression8084
mixture was incubated at 22 °C for 10 min. The reaction was stopped by
the addition of 20 l of 8 N HCl and 160 l of chloroform/methanol (1:1).
After centrifugation at 16,000  g for 10 min at room temperature, the
lower phase was applied to TLC plates coated with 1% potassium
oxalate, and the reaction products were separated in a TLC chamber
containing chloroform/methanol/water/ammonium hydroxide (60:47:
11.3:2) buffer. Following chromatography, the TLC plate was subjected
to autoradiography to visualize the phosphorylated substrate.
Western Blot Analysis—Cultured HSCs were washed with PBS, and
the cells were lysed with protein sample buffer (100 mM Tris-HCl (pH
6.8), 200 mM dithiothreitol, 4% SDS, 0.2% bromphenol blue, and 20%
glycerol). Protein concentrations were measured using the Bradford
method. Protein samples were heated at 95 °C for 5 min, and 20 g was
applied to a 10% SDS-polyacrylamide gel (7.5% SDS-polyacrylamide
gels were used for collagen analysis). After electrophoresis, the proteins
were electrophoretically transferred onto nitrocellulose membranes.
Membranes were stained with 0.5% Ponceau S to assure equal protein
loading and transfer. The membrane was blocked for 1 h with 5%
powdered milk in TBS-T. Afterward, the membrane was incubated with
the primary antibody: anti-phospho-Ser473 Akt or anti-total Akt poly-
clonal antibody (New England Biolabs Inc., Beverly, MA) diluted 1:1000
in 5% milk in TBS-T or anti-type I collagen polyclonal antibody (Rock-
land Inc., Gilbertsville, PA). The membrane was washed four times
with TBS-T for 15 min each wash and then incubated with horseradish
peroxidase-conjugated goat anti-rabbit IgG antibody diluted 1:1000 for
Akt and 1:5000 for collagen in 5% milk in TBS-T. The membrane was
washed five times with TBS-T for 10 min each wash. Immunodetected
proteins were visualized using the ECL assay kit.
RNase Protection Assay—RNase protection assays were performed
as described previously (27). Radiolabeled probes were prepared for rat
1(I) collagen (27) and glyceraldehyde-3-phosphate dehydrogenase
(pTRI-GAPDH-Rat, Ambion Inc., Austin, TX) and mixed with 5 g of
total RNA. Protected fragments were analyzed on standard 6% se-
quencing gels. Following electrophoresis, bands were visualized by au-
toradiography and quantitated by PhosphorImager analysis (Amer-
sham Biosciences).
Analysis of Type I Collagen Protein Expression—Proteins from the
culture medium were precipitated by the addition of ammonium sulfate
to 40% at 4 °C. Samples were centrifuged at 10,000  g for 30 min at
4 °C, and the pellet was suspended in 0.5 M acetic acid. Aliquots of the
protein sample were digested with 130 units of pepsin (Sigma), neu-
tralized with 1.5 M Tris-HCl (pH 8.8), and digested with 8 units of
collagenase (Sigma), or protein sample buffer was added. Digestion
reactions were performed at room temperature for 30 min. Samples
were applied onto a 7.5% polyacrylamide gel, and Western blot analysis
was performed for type I collagen as described above.
RESULTS
Ad5FAK-CD Infection Inhibits FAK Phosphorylation—Be-
cause homozygous FAK knockout mice are embryonic lethal
(28), we needed to develop a novel strategy to assess the role of
FAK in HSCs. To evaluate the effects of blocking FAK in
activated HSCs, culture-activated rat HSCs were transduced
with Ad5FAK-CD expressing a dominant-negative form of FAK
(23). The cells were immunostained 24 h after transduction for
the hemagglutinin epitope present on the FAK-CD protein. At
m.o.i.  500, 90% of the cells expressed the hemagglutinin-
tagged FAK-CD protein (data not shown). To determine
whether the dominant-negative FAK-CD protein effectively in-
hibits FAK phosphorylation, culture-activated HSCs were
transduced with either Ad5FAK-CD or control Ad5LacZ. Total
cell protein was harvested 48 h after infection and immunopre-
cipitated with anti-FAK antibody (recognizing the N-terminal
portion of FAK). Immunoprecipitated complexes were sub-
jected to SDS-PAGE, followed by immunoblotting for anti-FAK
or anti-phosphotyrosine antibody. The FAK-CD protein effec-
tively reduced the level of endogenous FAK protein in activated
HSCs and inhibited the level of phosphorylated endogenous
FAK (Fig. 1). The dual effects of down-regulating both FAK
protein levels and FAK phosphorylation by FAK-CD have been
observed in other cell types (23).
Blocking FAK or PI3K Inhibits PDGF-stimulated DNA Syn-
thesis in the HSC—To determine whether FAK has a role in
cell proliferation in culture-activated HSCs, we assessed
[3H]thymidine incorporation following Ad5FAK-CD transduc-
tion. Following Ad5FAK-CD transduction and a 24-h period of
serum starvation, HSC proliferation was stimulated with 20
ng/ml PDGF-BB. Ad5FAK-CD inhibited DNA synthesis in cul-
ture-activated HSCs by 49  0.2% (Fig. 2). Because PI3K is a
common downstream target of FAK, we assessed the role of
PI3K in PDGF-induced HSC proliferation. Culture-activated
HSCs were serum-starved for 24 h and then treated with 25 M
LY294002, a specific pharmacological inhibitor of PI3K, or
vehicle (Me2SO). Cells were treated with LY294002 for 1 h and
then stimulated with 20 ng/ml PDGF-BB. LY294002 treatment
blocked DNA synthesis by 70.2  0.17% in culture-activated
HSCs compared with control cells.
FAK and PI3K Are Important for HSC Adhesion and Cell
Migration—FAK is involved in cell adhesion (11). To determine
the role of FAK in adhesion of HSCs, we assayed HSC attach-
ment after trypsinizing and replating the cells following
Ad5FAK-CD transduction. Blocking FAK with the FAK-CD
protein inhibited HSC adhesion by 72.6  3.7% (Fig. 3A).
Treating the cells with 25 M LY294002 also inhibited cell
attachment by 76  4.0% (Fig. 3A).
Cell migration of culture-activated HSCs was assessed by
measuring the repair of a linear wound generated in a conflu-
FIG. 2. Blocking FAK inhibits proliferation of HSCs. Culture-
activated HSCs were left untreated or were infected with Ad5LacZ or
Ad5FAK-CD or treated with 25 M LY294002 or Me2SO (DMSO). Cells
were cultured in 0.2% serum to inhibit cell proliferation. Following 24 h
of serum starvation, the cells were stimulated to proliferate with 20
ng/ml PDGF for 48 h. During the last 24 h of incubation, 1 Ci/ml
[3H]thymidine was added. Control cells were maintained in 0.2% se-
rum. Data represent three independent experiments, each performed in
quadruplicate. *, p  0.01 versus rates in Ad5LacZ-infected HSCs; **,
p  0.01 versus rates in Me2SO-treated HSCs.
FIG. 1. FAK-CD reduces the level of FAK protein and the level
of phosphorylated FAK in HSCs. HSCs were transduced with the
control Ad5LacZ virus, which expresses -galactosidase, or with
Ad5FAK-CD (m.o.i.  500). Extracts of total cell proteins were immu-
noprecipitated (IP) with anti-FAK antibody (recognizing only the N-
terminal portion of the protein). The immunoprecipitated protein was
separated by SDS-PAGE, followed by immunoblotting (IB) for anti-FAK
(A) or anti-phosphotyrosine (B) antibody.
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ent monolayer of activated HSCs. Culture-activated HSCs
were transduced with Ad5FAK-CD prior to generating the
wound in a cell monolayer. Blocking FAK activity inhibited
migration of HSCs by 64.7  8.2% compared with transduced
control cells (Fig. 3B). Incubation of culture-activated HSCs
with 25 M LY294002 also inhibited cell migration by 58.7 
9.4% compared with cells treated with vehicle (Me2SO) (Fig.
3B). To assure that wound closure represents cell migration
and not a proliferative response, HSCs were treated with 2.5
M mitomycin C, an inhibitor of cell proliferation, 2 h prior to
generating the wound. Treatment of the cells with mitomycin C
did not affect wound closure, thus demonstrating that the
response measured cell migration and not cell proliferation.
Together, these data show that blocking either FAK or PI3K
inhibits cell adhesion and migration of HSCs.
PI3K Signals Downstream of FAK in the Activated HSC—
Inhibiting FAK or PI3K results in similar effects on HSC DNA
synthesis, cell adhesion, and cell migration, suggesting that
these signaling molecules are jointly involved in the cellular
signaling cascade meditating these cellular events. Therefore,
we wanted to determine whether PI3K acts downstream of
FAK in HSC signaling. Culture-activated HSCs were trans-
duced with either Ad5FAK-CD or Ad5LacZ or treated with 25
M LY294002. The cells were subsequently serum-starved to
reduce their proliferation rate and then induced to proliferate
with 20 ng/ml PDGF-BB. Total cell protein was immunopre-
cipitated with anti-PI3K antibody, and PI3K assays were per-
formed. The control Ad5LacZ virus did not affect PI3K activity;
however, infection with Ad5FAK-CD markedly inhibited PI3K
activity (Fig. 4). These data demonstrate that PI3K acts down-
stream of FAK in PDGF-stimulated HSC signaling.
Akt Phosphorylation Is Induced by Serum and PDGF in
HSCs—Akt has been implicated as a signaling molecule in
several cell types and is positioned downstream of PI3K. Be-
cause both serum and PDGF stimulated HSC proliferation, we
assessed whether serum and PDGF can induce Akt phospho-
rylation. Culture-activated HSCs were serum-starved for 48 h
and pretreated for 1 h with 25 M LY294002 prior to treatment
with either 10% serum or 20 ng/ml PDGF-BB. Cells were
harvested 10, 20, 30, and 60 min following stimulation, and Akt
phosphorylation status was assessed by Western blot analysis.
Within 10 min of serum (Fig. 5A) or PDGF-BB (Fig. 5B) stim-
ulation, phosphorylation of Akt at Ser473 was observed, indi-
cating Akt activation. Interestingly, Akt phosphorylation levels
began to diminish 60 min following serum stimulation. Pre-
treatment of the cells with 25 M LY294002 completely inhib-
ited both serum- and PDGF-induced Akt phosphorylation at
each time point. To assure equal protein loading, total Akt
levels were assessed and found to be similar (Fig. 5).
Akt Transmits Proliferative Signaling in HSCs—To assess
the role of Akt in HSC proliferation, culture-activated HSCs
were either transduced with Ad5myrAkt or Ad5dnAkt or
treated with LY294002. Afterward, the cells were serum-
starved for 48 h and then stimulated to proliferate with 10%
serum. The dominant-negative form of Akt and LY294002
treatment inhibited serum-induced HSC DNA synthesis by
72.6 and 92.7%, respectively (Fig. 6). Overexpression of the
constitutively active form of Akt stimulated HSC DNA synthe-
sis to levels equal to 10% serum (Fig. 6). LY294002 treatment
markedly inhibited HSC DNA synthesis. Cell counts (data not
shown) showed similar results, indicating that PI3K and Akt
are involved in transmitting proliferative signals in the HSC.
Akt Signals Downstream of FAK in PDGF-stimulated Acti-
vated HSCs—Because we demonstrated that PI3K signals
FIG. 3. Blocking FAK or PI3K inhibits adhesion and migration
of HSCs. A, to assess cell attachment, culture-activated HSCs were left
untreated, infected with Ad5LacZ or Ad5FAK-CD, or treated with 25
M LY294002 or Me2SO (DMSO). Twenty-four hours after viral infec-
tion or 30 min after LY294002 or Me2SO treatment, HSCs were de-
tached from culture dishes with trypsin. The detached cells were sus-
pended in Dulbecco’s modified Eagle’s medium containing 10% FBS and
then replated on tissue culture dishes. Two hours after replating, the
cells were washed twice with PBS to remove unattached cells,
trypsinized, and counted. Data represent three independent experi-
ments, each performed in quadruplicate. *, p  0.01 versus Ad5LacZ-
infected HSCs; **, p  0.01 versus Me2SO-treated HSCs. B, cell migra-
tion was assessed by measuring the repair of a linear wound generated
in a confluent monolayer of culture-activated HSCs. The distance cells
migrated from the front of the wound was measured using a micrometer
immediately after generating the wound and 24 h later. Culture-acti-
vated HSCs were left untreated, infected with Ad5LacZ or Ad5FAK-CD
for 24 h prior to creating the wound, or treated with the PI3K inhibitor
25 M LY294002 or its vehicle (Me2SO) 30 min prior to creating the
wound. Both Ad5FAK-CD and the PI3K inhibitor prevented migration
of culture-activated HSCs. Data represent three independent experi-
ments, each performed in triplicate. *, p  0.01 versus Ad5LacZ-trans-
duced HSCs; **, p  0.01 versus Me2SO-treated HSCs.
FIG. 4. PI3K signals downstream of FAK. Culture-activated HSCs
were infected with the control Ad5LacZ virus or with Ad5FAK-CD.
Total cell proteins were immunoprecipitated with anti-PI3K p110
antibody. Immunoprecipitates were assayed for PI3K activity by phos-
phorylation of phosphatidylinositol in the presence of [32P]ATP, and
phosphorylated products were detected by TLC, followed by autoradiog-
raphy. Data are representative of two separate experiments.
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downstream of FAK (Fig. 4), we wanted to determine whether
Akt also signals downstream of FAK following PDGF-induced
stimulation in activated HSCs. Culture-activated HSCs were
transduced with either Ad5FAK-CD or Ad5LacZ. The cells
were serum-starved to reduce their proliferation rate. After
48 h, the cells were induced to proliferate with 20 ng/ml PDGF-
BB. Cells were harvested after 20 min of PDGF stimulation,
and Western blot analysis was performed for phospho-Akt. The
control Ad5LacZ virus did not affect PDGF-induced phospho-
rylation of Akt; however, infection with Ad5FAK-CD inhibited
PDGF-induced Akt phosphorylation by 37% (Fig. 7). No
changes were observed in total Akt levels (Fig. 7). These data
demonstrate that Akt signals downstream of FAK in PDGF-
stimulated HSC signaling.
Transforming Growth Factor- (TGF-) Does Not Inhibit
PDGF-induced Akt Phosphorylation—TGF- has previously
been shown to inhibit HSC proliferation (29, 30). We wanted to
determine whether TGF- inhibits HSC proliferation at the
level of Akt phosphorylation following PDGF stimulation. Cul-
ture-activated HSCs were serum-starved for 48 h and then
treated under five different conditions: 1) 5 ng/ml TGF- for
1 h, 2) 20 ng/ml PDGF for 20 min, 3) 5 ng/ml TGF- for 1 h and
then 20 ng/ml PDGF for 20 min, 4) 5 ng/ml TGF- together
with 20 ng/ml PDGF for 20 min, and 5) pretreatment with 20
ng/ml PDGF for 10 min prior to treatment with 5 ng/ml TGF-.
TGF- treatment alone failed to stimulate Akt phosphorylation
and did not inhibit PDGF-induced phosphorylation of Akt
when added prior to, at the same time as, or after PDGF
stimulation (Fig. 8). Total Akt levels were equal at all points,
showing equal loading of the gel (Fig. 8). Therefore, TGF-
must exert its antiproliferative effects downstream of Akt
in HSCs.
Blocking PI3K Activity Inhibits 1(I) Collagen Expres-
sion—To assess whether PI3K is involved in regulating 1(I)
collagen gene expression, culture-activated HSCs were treated
with 25 M LY294002 for 24, 48, and 72 h in the presence of
10% serum, and 1(I) collagen mRNA levels were assessed by
RNase protection assays. After 24 h of LY294002 treatment, no
significant reduction in 1(I) collagen mRNA levels was de-
tected; however, 1(I) collagen mRNA levels were reduced to
46.6 and 27.4% of control Me2SO-treated cells after 48 and
72 h, respectively (Fig. 9). Type I collagen protein levels were
also examined in cell extracts and in the culture medium (Fig.
10A). LY294002 treatment did not reduce intracellular type I
collagen protein processing intermediates during the 72-h
treatment. However, secreted type I collagen protein levels
were markedly reduced after 24 and 48 h of LY294002 treat-
ment and were essentially undetected after 72 h of LY294002
treatment (Fig. 10A). As expected, only processing intermedi-
ates of type I collagen were detected intracellularly as assessed
by pepsin digestion, which cleaves the N- and C-propeptides off
the mature collagen triple-helical molecule (Fig. 10B). Diges-
tion with collagenase completely degraded the protein bands,
showing that they represent collagen proteins (Fig. 10B).
Akt Regulates 1(I) Collagen mRNA Expression—To investi-
gate whether Akt regulates type I collagen expression, culture-
activated HSCs were transduced with Ad5myrAkt or
Ad5dnAkt. As a control, cells were either uninfected or trans-
duced with Ad5LacZ. HSCs transduced with Ad5myrAkt
showed a 2.3-fold increase in 1(I) collagen mRNA expression
compared with control cells or cells transduced with either
FIG. 5. LY294002 inhibits serum- and PDGF-induced Akt phos-
phorylation. Activated HSCs were serum-starved for 48 h and then
treated with 25 M LY294002 for 1 h. Serum (10% final concentration)
(A) or 20 ng/ml PDGF-BB (B) was added to the cells for 0, 10, 20, 30, and
60 min. Total cell protein was harvested, and Western blot analysis was
performed using anti-phospho-Ser473 Akt (P-Akt; upper panels) or anti-
total Akt (lower panels) polyclonal antibody. Equal loading of the gels
was confirmed by Ponceau S staining of the transfer membrane (data
not shown).
FIG. 6. Akt stimulates HSC DNA synthesis. Culture-activated
HSCs were transduced with Ad5myrAkt or Ad5dnAkt. Cells were se-
rum-starved (0% serum) for 48 h to reduce the proliferation rate of the
cells. Proliferation was induced with 10% serum, and DNA synthesis
was assessed by [3H]thymidine incorporation. Cells were treated with
25 M LY294002 (LY) for 1 h prior to the addition of serum. Data
represent the average values obtained from two to eight different ex-
periments, each performed in quadruplicate. Error bars represent S.E.
Statistical analysis using the Mann-Whitney rank sum test showed the
following: *, p  0.05 compared with 0.2% serum; #, p  0.05 compared
with 10% serum; , p  0.05 compared with 0.2% serum.
FIG. 7. Blocking FAK activity inhibits PDGF-induced Akt
phosphorylation. Culture-activated HSCs were transduced with
Ad5LacZ or Ad5FAK-CD; and 24 h later, the cells were serum-starved
for 48 h. Cells were subsequently treated with or without 20 ng/ml
PDGF for 20 min. Total cell proteins were harvested, and Western blot
analysis was performed using anti-phospho-Ser473 Akt (upper panel) or
total Akt (lower panel) polyclonal antibody. Equal loading of the gel was
confirmed by Ponceau S staining of the transfer membrane (data not
shown). Densitometric analysis demonstrated a 37% reduction in phos-
pho-Akt levels in cells transduced with Ad5FAK-CD compared with
cells transduced with Ad5LacZ when normalized to total Akt levels.
Data are representative of two separate experiments.
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Ad5LacZ or Ad5dnAkt (Fig. 11A). The levels of intracellular
type I collagen protein were also increased by Ad5myrAkt,
whereas no effect on type I collagen protein levels were ob-
served in cells transduced with the control Ad5LacZ adenovirus
or Ad5dnAkt (Fig. 11B). No difference in the expression of
smooth muscle -actin protein levels, a standard measure of
HSC activation, was detected (data not shown).
DISCUSSION
Two major events occur following HSC activation that pro-
mote the fibrogenic response of these cells. First, HSCs change
their pattern of gene expression, increasing the synthesis and
deposition of extracellular matrix proteins and especially that
of type I collagen; hence, these cells become directly fibrogenic.
Second, the proliferation rate of HSCs increases, thereby effec-
tively amplifying the number of fibrogenic cells present in the
liver. Therefore, it is believed that effective treatment regimes
aimed at reducing or inhibiting either the fibrogenic or prolif-
erative responses of HSCs would reduce the deleterious effects
of HSCs in the progression of fibrosis.
PDGF is the most potent mitogenic factor for HSC prolifer-
ation (1). Several signaling pathways have been described that
regulate HSC proliferation involving cross-talk between the
different signaling pathways (Fig. 12). PDGF treatment of
HSCs activates Ras, followed by the sequential activation of
Raf, MEK, and ERK in HSCs (6, 10, 32). Activation of ERK is
observed following PDGF stimulation in culture-activated
HSCs and in HSCs isolated from animals treated with a single
dose of CCl4 (33). PDGF-induced ERK activation in human
HSCs is followed by transient up-regulation of c-fos expression
and AP-1 and STAT1 binding activities (34, 35). Blocking ERK
activity with the pharmacological inhibitor PD98059 inhibits
HSC proliferation along with AP-1 and STAT1 DNA-binding
activities, thus supporting a role for ERK activation in HSC
proliferation (33).
c-Jun and JNK are positive regulators of cell proliferation in
several cell types, including HSCs (36–38). Blocking JNK ac-
tivity in quiescent HSCs or in culture-activated HSCs with a
dominant-negative form of JNK prevents cell proliferation (38).
Interestingly, inhibition of p38 MAPK in either quiescent or
activated HSCs with the pharmacological inhibitor SB203580
actually increases cell proliferation, implying that activation of
p38 inhibits HSC proliferation (38). An inhibitory role for p38
in cell proliferation has been shown in other cell types, perhaps
by inhibiting cyclin D1 (39). Indeed, culture-induced prolifera-
tion of HSCs is associated with increased mRNA and protein
levels of cyclins D1, D2, and E (40).
PDGF also activates FAK, a member of the focal adhesion
complex family (12). This complex interacts with extracellular
matrix proteins through integrin interactions, providing a di-
rect sensor to the integrity and composition of the extracellular
environment. Following integrin activation, FAK is activated
by autophosphorylation (41). PDGF treatment of HSCs leads to
FAK phosphorylation that is blocked by a dominant-negative
form of Ras (42). Using a novel approach with an adenovirus
expressing a dominant-negative form of FAK, FAK-CD, we
FIG. 8. TGF- fails to inhibit PDGF-induced Akt phosphoryla-
tion. Culture-activated HSCs were serum-starved for 48 h. Cells were
treated under five conditions: 1) 5 ng/ml TGF- for 1 h, 2) 20 ng/ml
PDGF for 20 min, 3) 5 ng/ml TGF- for 1 h and then 20 ng/ml PDGF for
20 min, 4) 5 ng/ml TGF- together with 20 ng/ml PDGF for 20 min, and
5) 20 ng/ml PDGF for 10 min and then 5 ng/ml TGF- for 10 min. Total
cell proteins were harvested, and Western blot analysis was performed
using anti-phospho-Ser473 Akt (upper panel) or total Akt (lower panel)
polyclonal antibody. Equal loading of the gel was confirmed by Ponceau
S staining of the transfer membrane (data not shown). Co, control.
FIG. 9. Inhibition of PI3K inhibits 1(I) collagen mRNA expres-
sion. A, culture-activated HSCs were treated with 25 M LY294002
(LY) or Me2SO (DMSO) for 24, 48, and 72 h, and total RNA was
harvested. RNase protection assays were performed to assess the levels
of 1(I) collagen. Expression of 1(I) collagen mRNA is expressed rela-
tive to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Repre-
sentative RNase protection assay results are shown. The Control lane
represents RNA from untreated culture-activated HSCs, and tRNA was
also used in the assay as a negative control RNA sample. B, a graphical
analysis of the RNase protection assay data is shown. Data represent
results from two to four individual RNase assays. Error bars represent
S.E. Co, control.
FIG. 10. Inhibition of PI3K inhibits secreted type I collagen
protein expression, but does not affect intracellular levels of
type I collagen protein. A, HSCs were culture-activated, and total
cell protein and proteins obtained from the culture medium were
treated for 24, 48, or 72 h with 25 M LY294002 (LY) or Me2SO (DMSO)
as a control. Proteins were subjected to Western blot analysis for type I
collagen expression. B, to assess the identity of the different bands
detected, protein samples from the 24-h time points were subjected to
either pepsin or collagenase digestion. Pepsin reduced the two upper
bands to the lower band, indicating that the upper bands contain the N-
and/or C-terminal propeptides and showing that the lower band repre-
sents mature type I collagen. Collagenase digestion eliminated all
bands, indicating that all bands represent collagen.
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have shown that PDGF treatment activates and requires FAK
and Akt, a downstream target of FAK, for PDGF-induced HSC
proliferation as assessed by [3H]thymidine incorporation. We
also showed that FAK is positioned upstream of PI3K and Akt
in the proliferative response based on PI3K activity and the
phosphorylation status of Akt. FAK-CD overexpression also
results in decreased DNA synthesis in endothelial cells (11).
Overexpression of wild-type FAK increases cyclin D1 expres-
sion, decreases p21 expression, and accelerates G1-to-S phase
transition in NIH3T3 cells (43). Overexpression of dominant-
negative FAK blocks cyclin D1 up-regulation, induces p21 ex-
pression, and inhibits DNA synthesis in human foreskin fibro-
blast cells (43). Our data demonstrate that FAK plays a role in
DNA synthesis and cell proliferation in activated HSCs.
Integrin signaling through FAK has a role in regulating cell
spreading, migration, and proliferation. Cultured fibroblasts
isolated from FAK null mouse embryos, which demonstrate a
lethal phenotype, show reduced cell motility (28). Overexpress-
ing a dominant-negative form of FAK decreases cell spreading
and migration in endothelial umbilical vein cells (11). Simi-
larly, we demonstrated that inhibiting FAK blocks HSC migra-
tion. A role of FAK in cell adhesion has not been well estab-
lished. Cultured FAK/ cells do not show altered adhesion to
fibronectin (28). Overexpressing FAK in Chinese hamster
ovary cells has no effect on cell adhesion (44). However, it was
recently demonstrated that FAK is required for attachment of
a human melanoma cell line (45). We showed that FAK is
required for attachment of activated HSCs. Therefore, acti-
vated HSCs show a similar requirement of FAK for cell attach-
ment as shown in other nontransformed cells.
The PI3K-Akt pathway is also activated following PDGF
stimulation of HSCs (13). Akt can be activated not only by
growth factors that trigger tyrosine kinase activity or activa-
tion of cytokine receptors, but also by other signals that acti-
vate PI3K, including integrins, thus linking FAK activation to
this signaling pathway (18, 20). Activated Akt is a key down-
stream survival factor that stimulates cell proliferation and
inhibits apoptosis (31, 46, 47). Our studies confirm that acti-
vation of PI3K is important for HSC proliferation and chemo-
taxis (13). A role for PI3K in HSC proliferation is supported by
in vivo studies showing that, in rats, CCl4 treatment leads to
autophosphorylation of the PDGF receptor and increased PI3K
activity. Furthermore, inhibition of PI3K by wortmannin
blocks mitogenesis in response to PDGF, supporting the in-
volvement of this pathway in HSC proliferation (13). We and
others have shown similar results in HSC proliferation using a
more specific PI3K inhibitor, LY294002 (32). However, we pro-
vide additional support showing that the phosphorylation of
Akt at Ser473 is induced by serum or PDGF and is inhibited by
LY294002 and that this inhibits cell proliferation. Inhibition of
PI3K with wortmannin also reduces ERK activity and c-Fos
mRNA levels, suggesting that cross-talk occurs between the
PI3K and MAPK pathways following PDGF stimulation in
HSCs (34). The phosphorylation status of Akt correlated with
an increase in HSC proliferation, 1(I) collagen mRNA levels,
and type I collagen protein levels, demonstrating a regulatory
role of Akt in these processes. Inhibition of both PI3K with
LY294002 and Akt by adenovirus-mediated transduction of a
dominant-negative form of Akt markedly reduced HSC prolif-
eration. Transduction of HSCs with an adenovirus expressing a
constitutively active form of Akt induced HSC proliferation in
low serum conditions, thereby demonstrating that Akt is posi-
tioned downstream of PI3K and reaffirming its role in
HSC proliferation.
TGF-, the most potent fibrogenic cytokine in the HSC, did
not induce Akt phosphorylation in the HSC. This might be
related to the antiproliferative property of TGF- in HSCs (30).
TGF- failed to block Akt activation by PDGF when adminis-
tered prior to, at the same time as, or following PDGF treat-
ment. These results are similar to those of Chen et al. (48), who
found that suppression of the antiproliferative effect of TGF-
in human hepatoma cells (Hep3B) is dependent on the PI3K-
Akt pathway. This suggests that PDGF, as found in our study,
may impair the antiproliferative effect of TGF-.
HSC activation produces a dramatic induction of type I col-
lagen gene expression. We show here that PI3K is important in
FIG. 11. Akt stimulates 1(I) collagen mRNA and type I colla-
gen protein expression. A, culture-activated HSCs were transduced
at m.o.i.  500 with Ad5LacZ, Ad5dnAkt, or Ad5myrAkt. Total RNA
was isolated 7 days after transduction, and RNase protection assays
were performed for 1(I) collagen and -actin mRNA, which was used
as an internal control. Expression of 1(I) collagen mRNA is graphically
expressed relative to -actin (lower panel). B, culture-activated HSCs
were left untreated or transduced with Ad5LacZ, Ad5myrAkt, or
Ad5dnAkt. After 7 days of infection in growth conditions, total cell
proteins were harvested, and Western blot analysis was performed for
type I collagen. Equal loading of the gel was confirmed by Ponceau S
staining of the transfer membrane (data not shown).
FIG. 12. Proliferative signaling pathways in HSCs. PDGF-R,
PDGF receptor; ECM, extracellular matrix; PDK-1, phosphoinositide-
dependent kinase-1; D3PPIs, D3-phosphorylated phosphoinositols;
PtdIns, phosphatidylinositol; LY, LY294002; TAK, transforming
growth factor--activated kinase-1.
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regulating 1(I) collagen gene expression. Inhibition of PI3K
with LY294002 or Akt by adenovirus-mediated transduction of
a dominant-negative form of Akt markedly reduced 1(I) col-
lagen mRNA and type I collagen protein levels. Blocking PI3K
with LY294002 inhibited collagen expression at both the
mRNA and protein levels, similar to previously reported obser-
vations in lung fibroblasts (49). However, mRNA levels in
HSCs decreased at a much slower rate than in lung fibroblast
cells. This may reflect different half-lives of the 1(I) collagen
mRNA in the two cell types. Increased stability of 1(I) collagen
mRNA occurs following HSC activation mediated through pro-
tein interactions within the 3-untranslated region of the
mRNA molecule and is an important mechanism for controlling
1(I) collagen gene expression in the HSC (50, 51). Interest-
ingly, extracellular collagen protein levels were significantly
reduced within 24 h after inhibiting PI3K activity, whereas the
intracellular unprocessed collagen levels remained essentially
unchanged even after 72 h of treatment. This may reflect an
inhibition of collagen secretion following LY294002 treatment
with an accumulation of unprocessed intracellular collagen.
Because collagenase activity is primarily found extracellularly,
there may be no mechanism to degrade the unprocessed intra-
cellular collagen.
In summary, we have shown that the FAK-PI3K-Akt signal-
ing pathway is a critical pathway for PDGF-induce HSC pro-
liferation. Fig. 12 represents current knowledge for intracellu-
lar signaling leading to HSC proliferation. In addition, we have
demonstrated that PI3K is an important modulator of 1(I)
collagen gene expression. Together, this information indicates
that this signaling pathway may provide a potential therapeu-
tic target to modulate the fibrogenic response in the liver.
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